Biotech Values

[DewDiligence]

Teva’s Bill Marth may be in spin mode again vis-à-vis the Copaxone litigation. Marth said on today’s webcast that, following the judge’s denial of a summary judgment based on indefiniteness, there are no longer any differences in claims construction between Teva’s interpretation and NVS/MNTA’s interpretation. However, the table in the fourth linked document of #msg-54150823 includes differences in the parties’ interpretations of terms other than those relating to molecular weight, which the judge has not yet ruled on, as far as I know.